<DOC>
	<DOCNO>NCT01179607</DOCNO>
	<brief_summary>M0002 , orally active , selective non-peptidergic antagonist vasopressin V2 receptor inhibit vasopressin-induced water reabsorption kidney . Therefore aquaretic effect M0002 potential clinical benefit treatment ascites hyponatreamia cirrhotic patient .</brief_summary>
	<brief_title>Study Efficacy Vasopressin 2 Receptor Antagonist M0002 Treatment Ascites Cirrhotic Subjects With Hypo- Normonatraemia</brief_title>
	<detailed_description />
	<mesh_term>Ascites</mesh_term>
	<criteria>Main 1 . Subjects form cirrhosis ascites least 1 paracentesis least 4 liter last 6 month . 2 . Dose diuretic spironolactone furosemide stable least one week prior screen visit subject refractory diuretic . 3 . Subjects salt restrict diet ( &lt; 5.2 gram sodium/day , 90 mmol ) screening period prior trial drug administration . 4 . Other treatment management cirrhosis ascites stable least 2 week prior trial drug administration . 5 . ChildPugh B C liver cirrhosis score low 12 . 6 . Subjects hyponatraemia sodium level 120 132 mmol/l normonatraemia sodium level 133 145 mmol/l measure screening visit day 1 . Main 1 . Women child bear potential ( WOCBP ) 2 . Functional transjugular intrahepatic portasystemic stent shunt ( TIPS ) , peritoneovenous shunt 3 . Liver transplantation 4 . BuddChiari syndrome 5 . Unstable hepatic disease ( acute hepatitis , AST ALT &gt; 5 x upper limit normal , bilirubin &gt; 10 mg/dL )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>